Activation of the NMDA receptor involved in the alleviating after-effect of repeated stimulation of the subthalamic nucleus on motor deficits in hemiparkinsonian rats

Brain Research

Volumn 1306, Issue , 2010, Pages 159-167

  Akita, Hisanao ^a   Honda, Yuji ^a   Ogata, Masanori ^a   Noda, Kazuko ^a   Saji, Makoto ^a  

^a KITASATO UNIVERSITY   (Japan)

Author keywords

Behavioral test; Deep brain stimulation; Motor deficit; NMDA receptor antagonist; Rat model of Parkinson's disease; Subthalamic nucleus

Indexed keywords

4 (3 PHOSPHONOPROPYL) 2 PIPERAZINECARBOXYLIC ACID; DIZOCILPINE; N METHYL DEXTRO ASPARTIC ACID RECEPTOR; OXIDOPAMINE;

AKINESIA; ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ARTICLE; BRAIN DEPTH STIMULATION; CONTROLLED STUDY; MALE; MEDIAL FOREBRAIN BUNDLE; MOTOR ACTIVITY; MOTOR DYSFUNCTION; NONHUMAN; PARKINSONISM; PRIORITY JOURNAL; RAT; SUBTHALAMIC NUCLEUS;

RATTUS;

EID: 71549150964     PISSN: 00068993     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.brainres.2009.09.040     Document Type: Article

References (33)

1. Akita H., Ogata M., Jitsuki S., Ogura T., Oh-Nishi A., Hoka S., and Saji M. Nigral injection of antisense oligonucleotides to synaptotagmin I using HVJ-liposome vectors causes disruption of dopamine release in the striatum and impaired skill learning. Brain Res. 1095 (2006) 178-189
2. Barneoud A., Gao D.M., Ni Z.G., Pialla B., Bouali-Benazzouz, and Benabid A.L. Effect of high-frequency stimulation of the subthalamic nucleus on the neuronal activities of the substantia nigra pars reticulate and ventrolateral nucleus of the thalamus in rat. Neuroscience 99 (2000) 289-295
3. Bejjani B.P., Arnulf I., Demeret S., Damier P., Bonnet A.-M., Houeto J.-L., and Agid Y. Levodopa-induced dyskinesias in Parkinson's disease: is sensitization reversible?. Ann. Neurol. 47 (2000) 655-658
4. Benazzouz A., Gao D.M., Ni Z.G., Piallat B., Bouali-Benazzouz R., and Benabid A.L. Effect of high-frequency stimulation of the subthalamic nucleus on the neuronal activities of the substantia nigra pars reticulata and ventrolateral nucleus of the thalamus in the rat. Neuroscience 99 (2000) 289-295
5. Berman H., Wichman T., and DeLong M.R. Reversal of experimental parkinsonism by lesions of the subthalamic nucleus. Science 249 (1990) 1436-1438
6. Berman H., Wichman T., Karmon B., and DeLong M.R. The primate subthalamic nucleus. II. Neuronal activity in the MPTP model of Parkinsonism. J. Neurophysiol. 72 (1994) 507-520
7. Boulet S., Lacombe E., Carcenac C., Feuerstein C., Sgambato-Faure V., Poupard A., and Savasta M. Subthalamic stimulation-induced forelimb dyskinesias are linked to an increase in glutamate levels in the substantia nigra pars reticulate. J. Neurosci. 26 (2006) 10768-10776
8. Dallos V., Heathfield K., Stone P., and Allen F.A.D. Use of amantadine in Parkinson's disease: results of double-blind trial. Br. Med. J. 4 (1970) 24-26
9. Deep P., Dagher A., Sadikot A., Gjedde A., and Cumming P. Stumulation of dopa decarboxylase activity in striatum of healthy human brain secondary to NMDA receptor antagonism with a low dose of amantadine. Synapse 34 (1999) 313-318
10. Dostrovsky J.O., and Lozano A.M. Mechanism of deep brain stimulation. Mov. Disord. 17 Suppl. 3 (2002) S63-S68
11. Houeto J.-L., Welter M.-L., Bejjani P.B., du Montcel S.T., and Agid Y. Subthalamic stimulation in Parkinson disease: intraoperative predictive factors. Arch. Neurol. 60 (2003) 690-694
12. Kelsey J.E., Mague S.D., Pijanowski R.S., Harris R.C., Kleckner N.W., and Matthews R.T. NMDA receptor antagonists ameliorate the stepping deficits produced by unilateral medial forebrain bundle injections of 6-OHDA in rats. Psychopharmacology 175 (2004) 179-188
13. Kita H., Tachibana Y., Nambu A., and Chiken S. Balance of monosynaptic excitatory and disynaptic inhibitory responses of the globus pallidus induced after stimulation of the subthalamic nucleus in the monkey. J. Neurosci. 25 (2005) 8611-8619
14. Kitai S.T., and Deniau J.M. Cortical inputs to the subthamus: intracellular analysis. Brain Res. 214 (1981) 411-415
15. Kitai S.T., and Kita H. Anatomy and physiology of the subthalamic nucleus: a driving force of the basal ganglia. In: Carpenter M.B., and Jayaraman A. (Eds). The basal ganglia II. Structure and function-current concepts (1987), Plenum, New York 357-373
16. Krack P., Benazzouz A., Pollak P., Limousin P., Piallat B., Hoffmann D., Xie L., and Benabid A.L. Treatment of tremor in Parkinson's disease by subthalamic nucleus stimulation. Mov. Disord. 13 (1998) 907-914
17. Krack P., Betir A., Van Bercom N., and Chabardes S. Five-year follow-up of bilateral stimulation of the subthalamic nucleus in advanced Parkinson's disease. N. Engl. J. Med. 349 (2003) 1925-1934
18. Lang A.E., and Lozano A.M. Parkinson's disease First of two parts. N. Engl. J. Med. 339 (1998) 1044-1053
19. Lundblad M., Andersson M., Winkler C., Kirik D., Wierup N.A., and Cenci M.A. Pharmacological validation of behavioral measures of akinesia and dyskinesia in a rat model of Parkinson's disease. Eur. J. Neurosci. 15 (2002) 120-132
20. Miller W.C., and DeLong M.R. Altered tonic activity of neurons in the globus pallidus and subthalamic nucleus in the primate MPTP model of Parkinsonism. In: Carpenter M.B., and Jayaraman A. (Eds). The Basal Ganglia II Vol. 32 (1987), Plenum, New York
21. Mink J.W., and Thach W.T. Basal ganglia intrinsic circuits and their role in behavior. Curr. Opin. Neurobiol. 3 (1993) 950-957
22. Obeso J.A., Rodriguez-Oroz M.C., Rodoriguez M., DeLong M.R., and Olanow C.W. Pathophysiology of levodopa-induced dyskinesia in Parkinson's disease problems with the current model. Ann. Neurol. 47 Suppl. 1 (2000) S22-S32
23. Ogura T., Ogata M., Akita H., Jitsuki S., Akiba L., Noda K., Hoka S., and Saji M. Impaired acquisition of skilled behavior in rotarod task by moderate depletion of striatal dopamine in a pre-symptomatic stage model of Parkinson's disease. Neurosci. Res. 51 (2005) 299-308
24. Parent A., and Hazrati L.N. Functional anatomy of the basal ganglia. II. The place of subthalamic nucleus and external pallidum in basal ganglia circuitry. Brain Res. Brain Res. Rev. 20 (1995) 128-154
25. Parkes J.D., Calver D.M., Zikha K.J., and Knill-Jones R.P. Controlled trial of amantadine hydrochloride in Parkinson's disease. Lancet 1 (1970) 259-262
26. Perlmutter J.S., and Mink J.W. Deep brain stimulation. Annu. Rev. Neurosci. 29 (2006) 229-257
27. Schwab R.S., England A.C., Poskanzer D.C., and Young R.R. Amantadine in the treatment of Parkinson's disease. JAMA 208 (1969) 1168-1170
28. Shi L.-H., Woodward D.J., Luo F., Anstrom K., Schallert T., and Chang J.-Y. High-frequency stimulation of the subthalamic nucleus reverses limb-use asymmetry in rats with unilateral 6-hydroxydopamine lesions. Brain Res. 1013 (2004) 98-106
29. Shen K.Z., Zhu Z.T., Munhall A., and Johnson S.W. Synaptic plasticity in rat subthalamic nucleus induced by high-frequency stimulation. Synapse 50 (2003) 314-319
30. Ungerstedt U. Postsynaptic supersensitivity after 6-hydroxy-dopamine induced degeneration of the nigro-striatal dopamine system. Acta Physiol. Scand. 367 Suppl. (1971) 69-93
31. Ungerstedt U., and Herrera-Marschitz M. Behavioral pharmacology of dopamine receptor mechanisms. In: Stjarne L., Hedquist P., Lagerkrantz H., and Wenmalm A. (Eds). Chemical Neurotransmission: 75 years (1981), Academic Press, New York 481-494
32. Vezzani R., Serafini R., Stasi M.A., Caccia S., Conti I., Tridico R.V., and Samanin R. Kinetics of MK801 and its effect on quinolinic acid-induced seizures and neurotoxicity in rats. J. Pharmacol. Exp. Ther. 249 (1989) 278-283
33. Vingerhoets F.J., Villemure J.-G., Temperli P., Pollo C., Pralong E., and Ghika J. Subthalamic DBS replaces levodopa in Parkinson's disease: two-year follow-up. Neurology 58 (2002) 396-401